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Statin Therapy Resolves
Coronary Artery Inﬂammation
18F-ﬂuorodeoxyglucose (FDG) positron emission tomography
(PET) imaging has been commonly employed for the detec-
tion of malignant versus benign tumors. The selective uptake
of FDG in the malignant cells has been attributed to their
high metabolic activity. During such diagnostic studies, inci-
dental FDG uptake in the vascular tree has been observed
frequently and is considered to be reﬂective of atherosclerotic
plaque inﬂammation (1). Incidental FDG uptake is predomi-
nantly seen in the large vessels. The selective uptake has been
localized in macrophages, which are dependent on the exog-
enous source of glucose (1). The carotid FDG uptake is
seen in symptomatic patients, and anecdotal reports of theirFigure 1. Resolution of Coronary Inﬂammation in Response to Statin Trea
The electrocardiogramwas suggestive of an inferiormyocardial infarction (A), and
the right coronary artery (RCA) with an aneurysmmarked (B, black arrow). Multis
and an intense contrast effect in the aneurysm possibly indicative of inﬂammatio
emission tomography (PET) and coregistered CT scan demonstrated focal FDG up
arrowhead). A 3-month treatment with pitavastatin resolved the contrast intens
arrowhead) and resolved abnormal FDGuptake in FDG-PET imaging (C, bottom r
markers.FDG uptake in vascular inﬂammation are now available that
correlate with the circulating biomarkers of inﬂammation and
demonstrate resolution of inﬂammation in serial studies (2–4).
Statins have successfully resolved FDG uptake in carotid and
aortic vasculature. Imaging of inﬂammation in coronary ar-
teries, however, has been limited by the concurrent FDG
uptake in the myocardium, and intense dietary modiﬁcation
has been proposed for localization of plaque inﬂammation (2).
Whereas the efﬁcacy of statins is well demonstrated in the
carotid arteries and aorta, we observed a similar resolution of
inﬂammation in the coronary artery, as we shall discuss. Plaque
stabilization in response to statin therapy with an increase
in ﬁbrous cap thickness in coronary disease has just been
established, and we believe that resolution of inﬂammation
as described below provides the mechanistic basis of plaque
stabilization (5).tment
the coronary angiogram showedan abrupt occlusion of theproximal portion of
lice computed tomography (CT) angiography demonstrated an RCA aneurysm
n (C, top left, yellow arrowhead). 18F-ﬂuorodeoxyglucose (FDG) positron
take at the contrast-intense site in the RCA aneurysm (C, bottom left, red
ity in the RCA aneurysm in follow-up CT angiography (C, top right, yellow
ight, red arrowhead)with a concomitant reduction in the serum inﬂammatory
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1120A 32-year-old man presented with exertional dyspnea 14 months
after an episode of pericarditis. On admission, an electrocardiogram
was abnormal with prominent ST-segment elevation, abnormal Q
waves, and inverted T waves in leads II, III, and aVF (Fig. 1A).
Selective coronary angiography revealed an abrupt occlusion of the
proximal portion of right coronary artery (RCA) with an aneu-
rysmal dilation of the proximal RCA (Fig. 1B). The cardiac en-
zymes were not elevated. A recent Q-wave myocardial infarction of
uncertain age was considered. The erythrocyte sedimentation rate at
70 mm/h and C-reactive protein at 1.28 mg/dl were found to
be abnormal. The patient had no clinical evidence suggestive of
Kawasaki disease, Takayasu arteritis, immunoglobulin G4–related
pathology, and autoimmune or collagen vascular disease. The
remaining laboratory tests revealed dyslipidemia with serum tri-
glycerides level of 224 and high-density lipoprotein cholesterol level
of 25 mg/dl. A contrast-enhanced multislice computed tomography
(CT) angiography demonstrated an RCA aneurysm and intense
contrast effect of intravenous contrast media in the aneurysm
(Fig. 1C). The FDG PET/CT scan of the current patient
demonstrated a focal FDG uptake at the aneurysmal site in the
RCA (Fig. 1C). A treatment with pitavastatin 4 mg/day
was initiated. After a 3-month treatment of pitavastatin, high-
density lipoprotein cholesterol level remarkably increased by 46%
(from 25 to 37 mg/dl), whereas low-density lipoprotein cholesterol
level remained unchanged (from 61 to 65 mg/dl). Serum levels of
inﬂammatory biomarkers were decreased by about 50% (C-reactive
protein: 1.28 to 0.61 mg/dl; erythrocyte sedimentation rate: 70 to
38 mm/h). CT angiography at 3 months demonstrated an atten-
uation of intense contrast effect in the RCA aneurysm (Fig. 1C),
and the FDG PET/CT scan revealed almost complete resolution of
abnormal FDG uptake in the aneurysm (Fig. 1C). The current
report is encouraging in that prospective and serial imaging even in
coronary artery inﬂammation may become possible in the future.
Nobuhiro Tahara, MD, PhD,* Atsuko Tahara, MD,
Jagat Narula, MD, PhD, Tsutomu Imaizumi, MD, PhD
*Department of Medicine, Division of Cardiovascular Medicine, 67
Asahi-machi, Kurume 830-0011, Japan. E-mail: ntahara@med.
kurume-u.ac.jp
http://dx.doi.org/10.1016/j.jcmg.2013.02.013
Please note: Harold Strauss, MD, served as Guest Editor for this paper.
R E F E R E N C E S
1. Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of
vascular 18F-FDG uptake with vascular calciﬁcation. J Nucl Med 2005;
46:1278–84.
2. Narula J, Chandrashekhar Y. Molecular imaging of coronary inﬂamma-
tion: overcoming hurdles one at a time.. J Am Coll Cardiol Img 2010;3:
448–50.
3. Tezuka D, Haraguchi G, Ishihara T, et al. Role of FDG PET-CT in
Takayasu arteritis: sensitive detection of recurrences. J Am Coll Cardiol
Img 2012;5:422–9.
4. Myers KS, Rudd JH, Hailman EP, et al. Correlation between arterial
FDG uptake and biomarkers in peripheral artery disease. J Am Coll
Cardiol Img 2012;5:38–45.
5. Hattori K, Ozaki Y, Ismail TF, et al. Impact of statin therapy on plaque
characteristics as assessed by serial OCT, grayscale and integrated back-
scatter-IVUS. J Am Coll Cardiol Img 2012;5:169–77.LA Volume by CMR Distinguishes
Idiopathic From Pulmonary
Hypertension Due to HFpEF
There has been increasing recognition of pulmonary hypertension
(PH), which develops as a direct consequence of impaired left
ventricular distensibility and relaxation, described as PH due to
heart failure with preserved ejection fraction (PH-HFpEF) (1).
Current guidelines emphasize the importance of distinguishing PH-
HFpEF from idiopathic pulmonary arterial hypertension (IPAH), a
rare disease caused by progressive luminal obliteration of small
pulmonary arteries (2). At present, right heart catheterization
(RHC) is the deﬁnitive investigation to conﬁrm the diagnosis. In
this prospective study, we explored the use of cardiac magnetic
resonance (CMR)–derived left atrial volume (LAV) as a simple,
noninvasive method for distinguishing IPAH from PH-HFpEF,
without the need for additional variables or derived equations.
Consecutive treatment-naive patients with a suspected new diag-
nosis of pulmonary hypertension underwent diagnostic assessment
between January 2009 and March 2011. Patients with clear evidence
of an underlying cause of pulmonary hypertension such as chronic
thromboembolic disease, connective-tissue disease, left ventricular
(LV) systolic dysfunction, or signiﬁcant valvular heart disease on
echocardiography were excluded.
CMR imaging was performed in the supine position on a 1.5-T
magnetic resonance imaging scanner and images were analyzed
using the Argus analysis software (Houston, Texas). CMR images
were fully analyzed prior to RHC, but the analyzer was blinded to
the catheterization results. LAV was determined using standard 2-
and 4-chamber views and the biplane area-length method. Mea-
surements were made in accordance with previously published
methods (3).
RHC was performed within 72 h of CMR, with the patient in a
supine position breathing room air. Cardiac output was determined
using thermodilution. Following RHC, the diagnosis of IPAH or
PH-HFpEF was made according to current guidelines (2).
After RHC, 37 patients were diagnosed with IPAH, 21 patients
with PH-HFpEF, and 23 patients were found not to have pulmonary
hypertension. The IPAH group was younger, had lower systemic
blood pressure, and a lower incidence of diabetes mellitus and atrial
ﬁbrillation than the PH-HFpEF group did.
At CMR, in comparison to PH-HFpEF, IPAH patients had
increased right ventricular dilation, reduced right ventricular func-
tion, impaired LV ﬁlling, and lower left atrial volume (24  9 ml/m2
vs. 67  20 ml/m2, p < 0.0001) (Fig. 1).
Receiver-operating characteristic analysis of CMR-derived vari-
ables that differed between IPAH and PF-HFpEF demonstrated
that LAV was the most sensitive and speciﬁc variable to discrimi-
nate between the two conditions. Using a threshold LAV of
<43 ml/m2, IPAH could be distinguished from PH-HFpEF with
97% sensitivity and 100% speciﬁcity, with area under the receiver-
operating characteristic curve of 0.990.
With the global increase in hypertension, coronary artery disease,
and diabetes, PH-HFpEF is becoming more prevalent. One of
the most important diagnostic challenges for a pulmonary vascular
center is to distinguish IPAH from PH-HFpEF, particularly
since the emergence of PAH-speciﬁc therapies. These treatments
